Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tenecteplase - Genentech

Next Previous
X
Search
Drug Profile

Tenecteplase - Genentech

Alternative Names: IA TNK; Metalyse; Recombinant tissue plasminogen activator-Genentech; RG-3625; TNK; TNK-tPA; TNKase

Latest Information Update: 26 Dec 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Boehringer Ingelheim; Genentech; Roche Canada
  • Class Blood coagulation factors; Plasminogen activator enzymes; Serine endopeptidases; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myocardial infarction
  • Phase II SARS-CoV-2 acute respiratory disease
  • Discontinued Catheter thrombosis; Heart arrest; Stroke

Most Recent Events

  • 26 Dec 2023 3841904 - No updates (phase-IV trial data - NCT02777580)
  • 01 Nov 2023 Genentech completes the phase-II ALLY trial in Stroke (Adjunctive treatment) in USA (NCT05172934)
  • 08 Oct 2023 Boehringer Ingelheim completes the phase III PROBE trial in Stroke in China (IV) (NCT04915729)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top